Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease recurrence.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
290 participants in 2 patient groups
Loading...
Central trial contact
EORTC HQ
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal